Giovanni Manfredi Assanto | Ricerc@Sapienza

Pubblicazioni

Titolo	Pubblicato in	Anno
Impact of Daratumumab on Stem Cell Mobilization and Transplant in Patient with Newly Diagnosed Multiple Myeloma: A Real Word Single-Centre Study	MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES	2024
Evaluation of VTE-PREDICT Risk Score in Patients Receiving Low-Dose DOACs for Venous Thromboembolism (VTE) Secondary Prophylaxis	MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES	2024
Secondary Prophylaxis of Venous Thromboembolism (VTE) with Low Dose Apixaban or Rivaroxaban: Results from a Patient Population with More than 2 Years of Median Follow-up	MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES	2024
Benefits and Safety of Empiric Antibiotic Treatment Active Against KPC-K. pneumoniae in Febrile Neutropenic Patients with Acute Leukemia Who are Colonized with KPC-K. pneumoniae. A 7-Years Retrospective Observational Cohort Study	INFECTION AND DRUG RESISTANCE	2023
Whole body MRI with Difusion Weighted Imaging versus 18F‑fuorodeoxyglucose‑PET/CT in the staging of lymphomas	LA RADIOLOGIA MEDICA	2023
Whole body MRI with Diffusion Weighted Imaging versus 18F-fluorodeoxyglucose-PET/CT in the staging of lymphomas	LA RADIOLOGIA MEDICA	2023
Achieving the Cure of Follicular Lymphoma: is it Time to Finalize Treatment Strategies to Reach This Goal in a Subset of Patients?	MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES	2023
Research Topic: Measurable Residual Disease in Hematologic Malignancies. Can digital droplet {PCR} improve measurable residual disease monitoring in chronic lymphoid malignancies?	FRONTIERS IN ONCOLOGY	2023
Impact of Sars-CoV-2 Prophylaxis with Tixagevimab-Cilgavimab in High-Risk Patients with B-Cell Malignancies: A Single-Center Retrospective Study	MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES	2023
Antithrombotic secondary prophylaxis with low dose of apixaban or rivaroxaban in the onco-hematologic patients: comparison with non-neoplastic patients	ANNALS OF HEMATOLOGY	2023
Early clearance of hairy cell leukaemia in the bone marrow after first‐line treatment with cladribine predicts a favourable outcome	BRITISH JOURNAL OF HAEMATOLOGY	2023
Secondary prophylaxis of venous thromboembolism with direct oral anticoagulants: comparison between patients with major congenital thrombophilia versus non-thrombophilic patients	INTERNAL AND EMERGENCY MEDICINE	2022
Lymphadenopathies before and during the pandemic COVID-19: increasing incidence of metastases from solid tumors	JOURNAL OF CLINICAL MEDICINE	2022
Novel therapeutic agents for myelofibrosis after failure or suboptimal response to JAK2 inhbitors	CURRENT OPINION IN ONCOLOGY	2022
RR6 prognostic model provides information about survival for myelofibrosis treated with ruxolitinib: validation in a real-life cohort	BLOOD ADVANCES	2022
Extranodal Marginal Zone Lymphoma: Pathogenesis, Diagnosis and Treatment	CANCERS	2022
From bench to bedside: bridging the gaps in best practices for real-world chronic myeloid leukemia care	EXPERT REVIEW OF HEMATOLOGY	2022
Asciminib in chronic myeloid leukemia	DRUGS OF TODAY	2022
Direct oral anticoagulants for the treatment of atrial fibrillation in patients with hematologic malignancies	JOURNAL OF THROMBOSIS AND THROMBOLYSIS	2022
"Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients-30 months follow-up": Comment from Serrao et al	JOURNAL OF THROMBOSIS AND HAEMOSTASIS	2022